Partnership update
OPKO's quarterly filing with the U.S. Securities and Exchange Commission reports that EirGen and NICOYA Macau Limited amended their license agreement on April 30, 2026, supporting RAYALDEE development and commercialization in Greater China.
Greater China focus
The update continues a regional development and commercialization framework established in 2021. The official release also notes that RAYALDEE is approved in Macau. Any timing for other markets remains forward-looking and subject to formal regulatory and company updates.
NICOYA's role
NICOYA advances regional R&D collaboration and scientific communication around calcifediol-related products with partners across Greater China. Product information and eligible populations depend on local approvals and professional advice.